CTLA4 and neoplasm: The conversion of the tumor microenvironment by OVs to a more favorable state can improve with the immunomodulatory effects of immune checkpoint blockade, as demonstrated in recent phase I and II trials that showed both, promising response rates as well as acceptable toxicity in combination treatments of OVs with either anti-CTLA4 or anti-PD1 therapy [20–22].